Search results
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
GuruFocus.com via Yahoo Finance· 6 days agoRobust portfolio of rare-disease therapies with a focus on genetic discovery. Strategic positioning...
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares have...
BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales
Zacks via Yahoo Finance· 1 year agoBioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat...
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 45%...
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights The projected fair value for BioMarin Pharmaceutical is US$166 based on 2 Stage Free...
BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut
Zacks via Yahoo Finance· 6 months agoBioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company...
BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU
Zacks via Yahoo Finance· 2 years agoBioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the...
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
Zacks via Yahoo Finance· 2 years agoBioMarin Pharmaceutical BMRN reported adjusted earnings of 45 cents per share in third-quarter 2022,...
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out...
Zacks via Yahoo Finance· 2 years agoBioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely...
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance
Zacks via Yahoo Finance· 2 years agoIf approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for...
Wall Street Analysts See a 31% Upside in BioMarin (BMRN): Can the Stock Really Move This High?
Zacks via Yahoo Finance· 2 years agoThe mean of analysts' price targets for BioMarin (BMRN) points to a 30.9% upside in the stock. While...